TY - JOUR T1 - The Effect of Hyperuricemia and Allopurinol Treatment Outcome of Greft in Kidney Transplant Recipients TT - Böbrek Nakil Hastalarında Hiperürisemi ve Allopuirnol Tedavisinin Graft Sonlanımına Etkileri AU - Paydas, Saime AU - Yücel, Neşat AU - Nazlıcan, Ersin AU - Unal, İlker PY - 2023 DA - December Y2 - 2023 DO - 10.36516/jocass.1320561 JF - Journal of Cukurova Anesthesia and Surgical Sciences JO - J Cukurova Anesth Surg PB - Merthan TUNAY WT - DergiPark SN - 2667-498X SP - 483 EP - 487 VL - 6 IS - 3 LA - en AB - Introduction: Kidney transplant recipients(KTRs) may have high level of serum uric acid(SUA) due to greft dysfunction and immunosuppressives. In this study, we evaluated effect of high SUA levels and allopurinol therapy in KTRs on renal functions.Patients and Methods: 113 of 233 KTRs had elevated SUA level(G1). Fiftyseven of G1 received allopurinol treatment(G1A+) and 56 patients G1A-) did not. 56 of 118 patients who were followed for five years(G5) were hyperuricemic(G5-1) and 26 of G5-1 treated with allopurinol(G5-1A+) and 30 of them did not(G5-1A-). 62 patients were normourisemic(G5-2). GFR KW - : Uric acid KW - renal dysfunction KW - allopurinol KW - kidney transplant recipient N2 - Giriş: Böbrek nakli alıcılarında; greft disfonksiyonu ve kullanılan immünsüpresifler nedeniyle serum ürik asit(SUA) seviyesi artabilir. Çalışmamızda, böbrek nakli alıcılarında yüksek SUA düzeyleri ve allopurinol tedavisinin böbrek fonksiyonları üzerindeki etkileri değerlendirildi.Hastalar ve Yöntemler: Çalışmaya alınan 233 böbrek nakli alıcılarından 113’ünde SUA düzeyi yüksek idi (G1). G1'de allopurinol tedavisini 57 hasta(G1A+) aldı ve 56 hasta(G1A-) almadı. Beş yıl takip edilen (G5) 118 hastanın 56'sında hiperürisemi (G5-1) saptandı. G5-1'de 26 hasta allopurinol (G5-1A+) ile tedavi edildi, 30 hastada allopurinol verilmemiş idi (G5-1A-). G5’de 62 hasta normourisemikti (G5-2). Glomerül filtrasyon hızı CR - 1. Clive DM. Renal transplant-associated hyperuricemia and gout. J Am Soc Nephrol. 2000; 11(5): 974-9. https://doi.org/10.1681/ASN.V115974 CR - 2. Weiner DE, Tighiouart H, Elsayed EF, et al. Uric acid and incident kidney disease in the community. J Am Soc Nephrol. 2008; 19(6): 1204-11. https://doi.org/10.1681/ASN.2007101075 CR - 3. Obermayr RP, Temml C, Gutjahr G, et al. Elevated uric acid increases the risk of kidney disease. J Am Soc Nephrol. 2008; 19(12): 2407-13. https://doi.org/10.1681/ASN.2008010080 CR - 4. Han M, Lee JP, Park S, et al. Early onset hyperuricemia is a prognostic marker for kidney graft failure: Propensity score matching analysis in a Korean multicenter cohort. PLoS One. 2017;12(5):e0176786. https://doi.org/10.1371/journal.pone.0176786 CR - 5. Kim KM, Kim SS, Han DJ, et al. Hyperuricemia in kidney transplant recip-ients with intact graft function. Transplant Proc. 2010; 42(9): 3562-7. https://doi.org/10.1016/j.transproceed.2010.07.104 CR - 6. Saglam F, Celik A, Sarioglu S, et al. Hyperuricemia influences chronic cyclosporine nephropathy. Transplant Proc. 2008; 40(1): 167-70. https://doi.org/10.1016/j.transproceed.2007.11.013 CR - 7. Armstrong KA, Johnson DW, Campbell SB, et al. Does uric acid have a pathogenetic role in graft dysfunction and hypertension in renal trans-plant recipients? Transplantation. 2005; 80(11): 1565-71. https://doi.org/10.1097/01.tp.0000183895.88572.13 CR - 8. Kanbay M, Huddam B, Azak A, et al. A randomized study of allopurinol on endothelial function and estimated glomerular filtration rate in asymp-tomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol. 2011; 6(8): 1887-94. https://doi.org/10.2215/CJN.11451210 CR - 9. Akgul A, Bilgic A, Ibis A, et al. Is uric acid a predictive factor for graft dysfunction in renal transplant recipients? Transplant Proc. 2007; 39(4): 1023-6. https://doi.org/10.1016/j.transproceed.2007.03.028 CR - 10. Malheiro J, Almeida M, Fonseca I, et al. Hyperuricemia in adult renal allograft recipients: prevalence and predictors. Transplant Proc. 2012; 44(8): 2369-72. https://doi.org/10.1016/j.transproceed.2012.07.033 CR - 11. Lin HY, Rocher LL, McQuillan MA, et al. Cyclosporine-induced hyperu-ricemia and gout. N Engl J Med. 1989; 321(5): 287-92. https://doi.org/10.1056/NEJM198908033210504 CR - 12. Numakura K, Satoh S, Tsuchiya N, et al. Hyperuricemia at 1 year after renal transplantation, its prevalence, associated factors, and graft survival. Transplantation. 2012; 94(2): 145-51. https://doi.org/10.1097/TP.0b013e318254391b CR - 13. Gerhardt U, Grosse Hüttmann M, Hohage H. Influence of hyperglycemia and hyperuricemia on long-term transplant survival in kidney transplant recipients. Clin Transplant. 1999; 13(5): 375-9. https://doi.org/10.1034/j.1399-0012.1999.130502.x CR - 14. Iseki K, Ikemiya Y, Inoue T, et al. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis. 2004; 44(4): 642-50. https://doi.org/10.1016/S0272-6386(04)00934-5 CR - 15. Hart A, Jackson S, Kasiske BL, et al. Uric acid and allograft loss from interstitial fibrosis/tubular atrophy: post hoc analysis from the angioten-sin II blockade in chronic allograft nephropathy trial. Transplantation. 2014; 97(10): 1066-71. https://doi.org/10.1097/01.TP.0000440952.29757.66 CR - 16. Min SI, Yun IJ, Kang JM, et al. Moderate-to-severe early-onset hyperu-ricemia: a prognostic marker of long-term kidney transplant outcome. Nephrol Dial Transplant. 2009; 24(8): 2584-90. https://doi.org/10.1093/ndt/gfp192 CR - 17. Akalin E, Ganeshan SV, Winston J, Muntner P. Hyperuricemia is associ-ated with developing the composite outcomes of new cardiovascular events and chronic allograft nephropathy. Transplantation. 2008; 86(5): 652-8. https://doi.org/10.1097/TP.0b013e3181814f5b CR - 18. Meier-Kriesche HU, Schold JD, Vanrenterghem Y, et al. Uric acid levels have no significant effect on renal function in adult renal transplant recipi-ents: evidence from the symphony study. Clin J Am Soc Nephrol. 2009; 4(10): 1655-60. https://doi.org/10.2215/CJN.02700409 CR - 19. Kim ED, Famure O, Li Y, et al. Uric acid and the risk of graft failure in kidney transplant recipients: a re-assessment. Am J Transplant. 2015; 15(2): 482-8. https://doi.org/10.1111/ajt.13000 CR - 20. Liu X, Zhai T, Ma R, et al. Effects of uric acid-lowering therapy on the progression of chronic kidney disease: a systematic review and meta-analysis. Ren Fail. 2018; 40(1): 289-97. https://doi.org/10.1080/0886022X.2018.1456463 CR - 21. Yang H, Li R, Li Q, et al. Effects of febuxostat on delaying chronic kidney disease progression: a randomized trial in China. Int Urol Nephrol. 2023; 55(5): 1343-52. https://doi.org/10.1007/s11255-022-03437-5 CR - 22. Bandukwala F, Huang M, Zaltzman JS, et al. Association of uric acid with inflammation, progressive renal allograft dysfunction and post-transplant cardiovascular risk. Am J Cardiol. 2009; 103(6): 867-71. https://doi.org/10.1016/j.amjcard.2008.11.042 CR - 23. Osadchuk L, Bashir MH, Tangirala B, et al. Effect of allopurinol on slow-ing allograft functional decline in kidney transplant recipients. Exp Clin Transplant. 2014; 12(3): 190-4. UR - https://doi.org/10.36516/jocass.1320561 L1 - https://dergipark.org.tr/en/download/article-file/3235277 ER -